Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Since September 2012, the marketing licence in the UK has been held by Flynn Pharma Ltd, of Dublin, Ireland , and the product, although identical, has been called Phenytoin Sodium xx mg Flynn Hard Capsules. (The xx mg in the name refers to the strength—for example 'Phenytoin sodium 25 mg Flynn Hard Capsules').  The capsules are still made by Pfizer 's Goedecke subsidiary's plant in Freiburg , Germany and they still have Epanutin printed on them.  After Pfizer's sale of the UK marketing licence to Flynn Pharma, the price of a 28-pack of 25 mg phenytoin sodium capsules marked Epanutin rose from 66p (about $) to £ (about $). Capsules of other strengths also went up in price by the same factor—2384%,  costing the UK's National Health Service an extra £43 million (about $ million) a year.  The companies were referred to the Competition and Markets Authority who found that they had exploited their dominant position in the market to charge “excessive and unfair” prices. 
Treatment of the acute attack: 800 mg (620 mg base) followed in 6 to 8 hours by 400 mg (310 mg base), then 400 mg (310 mg base) once a day for 2 consecutive days; alternatively, a single dose of 800 mg (620 mg base) has also been effective
Dosage on the basis of body weight:
First dose: 10 mg base/kg (not to exceed 620 mg base)
Second dose: 5 mg base/kg (not to exceed 310 mg base) 6 hours after first dose
Third dose: 5 mg base/kg 18 hours after second dose
Fourth dose: 5 mg base/kg 24 hours after third dose
Each dose should be taken with a meal or a glass of milk.
Concomitant therapy with an 8-aminoquinoline drug is necessary for the radical cure of vivax and malariae malaria.